Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Clinical Trial ID NCT02736552

Rank	Title	Journal	Year	PubWeight™‹?›
1	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.	Lancet	2012	6.83
2	Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.	J Clin Oncol	2011	6.53
3	Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.	J Clin Oncol	1998	2.51
4	Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.	Lancet Oncol	2014	1.99
5	No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.	Am J Clin Oncol	2011	0.82
6	[Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].	Zhonghua Wei Chang Wai Ke Za Zhi	2014	0.75
7	Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer.	PLoS One	2013	0.75